Michael Kurowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael Kurowski has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
A Sawyer
London School of Economics, London, UK
2 shared publicationsS Staszewski
2 shared publicationsA Arslan
1 shared publicationA Hill
Roche, Welwyn, UK, and
1 shared publicationA Mroziekiewicz
1 shared publicationA Müller
1 shared publication
Latest Publications
- 30 June 2006
- Vol. 11 (6) , 236-44
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
The authors evaluated the pharmacokinetics and tolerability of indinavir/lopinavir/ritonavir in a protease inhibitor only combination. Plasma drug levels of patients taking indinavir/lopinavir/ritonavir 800/400/100mg twice daily (n = 24, group 1) were compared to patients taking either lopinavir/ritonavir 400/100mg (n = 35, group2) or indinavir/ritonavir 800/100mg (n = 33, group3) twice daily plus nucleos(t)ide reverse transcriptase inhibitors (NRTI). Steady-state drug concentrations were measured by LC/MS/MS. Minimum and maximum concentrations (C subsetmin, C subsetmax), area under the concentration-time curve (AUC subset0-12h), total clearance (CL subsettot) and half-life (t1/2) were calculated. HIV viral load, CD4 cell count and adverse events causing early termination of therapy were correlated over a period of 48 weeks. Plasma levels of lopinavir/ritonavir were significantly enhanced when combined with indinavir compared to a regimen of lopinavir/ritonavir+NRTI: Mean lopinavir AUC subset(0-12h) 80,912 ng*h/mL vs. 60,548 ng*h/mL; C subsetmin 4,633 ng/mL vs. 3,258 ng/mL; C subsetmax 8,023 ng/mL vs. 6,710 ng/mL. Mean ritonavir AUC(0-12h) 6,907 ng*h/mL vs. 3,467 ng*h/mL; Cmin 220 ng/mL vs. 125 ng/mL; C subsetmax 1,059 ng/mL vs. 522 ng/mL. Indinavir levels were comparable for both indinavir containing regimen. A significantly smaller number of patients stopped indinavir/lopinavir/ritonavir therapy (group1: 16.7%) than indinavir/ritonavir + NRTI treatment (group3: 45.5%) due to adverse events. Virological failure was the main reason for early termination of treatment with indinavir/lopinavir/ ritonavir before week 48 (group1: 50%). indinavir/lopinavir/ritonavir 800/400/ 100mg twice daily represents a therapy option with an adequate safety but only short term efficacy for extensively pretreated patients.
- 30 June 2006
- Vol. 11 (6) , 236-44
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
The authors evaluated the pharmacokinetics and tolerability of indinavir/lopinavir/ritonavir in a protease inhibitor only combination. Plasma drug levels of patients taking indinavir/lopinavir/ritonavir 800/400/100mg twice daily (n = 24, group 1) were compared to patients taking either lopinavir/ritonavir 400/100mg (n = 35, group2) or indinavir/ritonavir 800/100mg (n = 33, group3) twice daily plus nucleos(t)ide reverse transcriptase inhibitors (NRTI). Steady-state drug concentrations were measured by LC/MS/MS. Minimum and maximum concentrations (C subsetmin, C subsetmax), area under the concentration-time curve (AUC subset0-12h), total clearance (CL subsettot) and half-life (t1/2) were calculated. HIV viral load, CD4 cell count and adverse events causing early termination of therapy were correlated over a period of 48 weeks. Plasma levels of lopinavir/ritonavir were significantly enhanced when combined with indinavir compared to a regimen of lopinavir/ritonavir+NRTI: Mean lopinavir AUC subset(0-12h) 80,912 ng*h/mL vs. 60,548 ng*h/mL; C subsetmin 4,633 ng/mL vs. 3,258 ng/mL; C subsetmax 8,023 ng/mL vs. 6,710 ng/mL. Mean ritonavir AUC(0-12h) 6,907 ng*h/mL vs. 3,467 ng*h/mL; Cmin 220 ng/mL vs. 125 ng/mL; C subsetmax 1,059 ng/mL vs. 522 ng/mL. Indinavir levels were comparable for both indinavir containing regimen. A significantly smaller number of patients stopped indinavir/lopinavir/ritonavir therapy (group1: 16.7%) than indinavir/ritonavir + NRTI treatment (group3: 45.5%) due to adverse events. Virological failure was the main reason for early termination of treatment with indinavir/lopinavir/ ritonavir before week 48 (group1: 50%). indinavir/lopinavir/ritonavir 800/400/ 100mg twice daily represents a therapy option with an adequate safety but only short term efficacy for extensively pretreated patients.
- 26 April 2004
- p. 62-4
[Determination of serum levels of antiretroviral drugs].
- 1 January 2004
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 24 (1) , 49-53
Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.
- 1 January 2004
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 24 (1) , 49-53
Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.
- Open Access
- 1 April 2003
- Published by Wiley in HIV Medicine
- Vol. 4 (2) , 94-100
Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
- 1 April 2003
- Published by Wiley in HIV Medicine
- Vol. 4 (2) , 94-100
Open AccessPharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
- 29 October 2002
- Vol. 7 (10) , 453-6
Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily.
The objective of the study was to investigate the effect of two different breakfasts on the pharmacokinetics of nelfinavir under steady state conditions. Twenty-four healthy male volunteers were evaluated in a 17 days open labeled one sequence crossover study evaluating the effect of a 'light' breakfast (350 kcal) compared to a standard breakfast (800 kcal) on the pharmacokinetics of nelfinavir at steady state during 1250 mg twice daily (BID) administration. After administration with a standard breakfast higher concentrations of nelfinavir were observed during the terminal phase than after administration with a 'light' breakfast. The comparison of the log subset 10 transformed parameters C subset 1-hr-postdose, AUC subset 0-12h, C subset max, and C subset 12 hours, showed that the AUC subset 0-12h was decreased by 13% (P = 0.01) after administration with the 'light' breakfast. Nelfinavir 1250 mg BID was well tolerated. Although drug intake with a 'light' breakfast' showed a statistically significant decrease for nelfinavir AUC subset 0-12h, this marginal 13% reduction is not considered clinically relevant. No significant effects of the two different breakfasts were found for the remaining three parameters tested C subset 1-hr-postdose, C subset max, and C subset 12 hours.
- 29 October 2002
- Vol. 7 (10) , 453-6
Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily.
The objective of the study was to investigate the effect of two different breakfasts on the pharmacokinetics of nelfinavir under steady state conditions. Twenty-four healthy male volunteers were evaluated in a 17 days open labeled one sequence crossover study evaluating the effect of a 'light' breakfast (350 kcal) compared to a standard breakfast (800 kcal) on the pharmacokinetics of nelfinavir at steady state during 1250 mg twice daily (BID) administration. After administration with a standard breakfast higher concentrations of nelfinavir were observed during the terminal phase than after administration with a 'light' breakfast. The comparison of the log subset 10 transformed parameters C subset 1-hr-postdose, AUC subset 0-12h, C subset max, and C subset 12 hours, showed that the AUC subset 0-12h was decreased by 13% (P = 0.01) after administration with the 'light' breakfast. Nelfinavir 1250 mg BID was well tolerated. Although drug intake with a 'light' breakfast' showed a statistically significant decrease for nelfinavir AUC subset 0-12h, this marginal 13% reduction is not considered clinically relevant. No significant effects of the two different breakfasts were found for the remaining three parameters tested C subset 1-hr-postdose, C subset max, and C subset 12 hours.
- 26 March 1999
- Vol. 4 (3) , 101-4
Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Dual protease inhibitor (PI) therapy has been established either in order to increase plasma concentrations of one PI or to combine synergistic effects of two PI's on viral load. Studies with saquinavir (SQV) and small doses of ritonavir (RTV) as well as experiences from our therapeutic drug monitoring suggest that single daily doses may result in sufficient SQV serum levels throughout an interval of 24 h. A controlled, randomized trial with 20 healthy men was conducted for the comparison of serum levels with 1600 mg SQV (group 1) or 1600 mg SQV/200 mg RTV (group 2). The dosages were selected in order to use RTV as an inhibitor of cytochrome P450 3A4 and SQV as protease inhibitor. The volunteers received single daily doses following a standardized breakfast on 3 consecutive days. Serum samples were analyzed for SQV and RTV employing LC-tandem mass spectrometry. The minimum concentration of saquinavir after 24 hours, the AUC, the maximum concentration and the serum half-lives on day 3 served as target parameters. The minimum SQV concentration amounted to 469.4 ng/ml, when combined with RTV and proved to be significantly higher (p <0.05) than the corresponding concentration with SQV alone (127.3 ng/ml). The SQV maximum concentration was raised approximately 6fold and the AUC 9fold when RTV was coadministered. In combination with 200 mg of RTV the predominant elimination half-life of SQV increased from 2.6 to 6.45 hours. These data prove that under single daily doses of 1600 mg SQV/200 mg RTV HIV-inhibitory concentrations of SQV can be achieved for 24 hours. Due to the high variability of the concentrations, which can be seen with all PI s, we recommend continuous therapeutic drug monitoring of serum trough levels.
- 26 March 1999
- Vol. 4 (3) , 101-4
Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Dual protease inhibitor (PI) therapy has been established either in order to increase plasma concentrations of one PI or to combine synergistic effects of two PI's on viral load. Studies with saquinavir (SQV) and small doses of ritonavir (RTV) as well as experiences from our therapeutic drug monitoring suggest that single daily doses may result in sufficient SQV serum levels throughout an interval of 24 h. A controlled, randomized trial with 20 healthy men was conducted for the comparison of serum levels with 1600 mg SQV (group 1) or 1600 mg SQV/200 mg RTV (group 2). The dosages were selected in order to use RTV as an inhibitor of cytochrome P450 3A4 and SQV as protease inhibitor. The volunteers received single daily doses following a standardized breakfast on 3 consecutive days. Serum samples were analyzed for SQV and RTV employing LC-tandem mass spectrometry. The minimum concentration of saquinavir after 24 hours, the AUC, the maximum concentration and the serum half-lives on day 3 served as target parameters. The minimum SQV concentration amounted to 469.4 ng/ml, when combined with RTV and proved to be significantly higher (p <0.05) than the corresponding concentration with SQV alone (127.3 ng/ml). The SQV maximum concentration was raised approximately 6fold and the AUC 9fold when RTV was coadministered. In combination with 200 mg of RTV the predominant elimination half-life of SQV increased from 2.6 to 6.45 hours. These data prove that under single daily doses of 1600 mg SQV/200 mg RTV HIV-inhibitory concentrations of SQV can be achieved for 24 hours. Due to the high variability of the concentrations, which can be seen with all PI s, we recommend continuous therapeutic drug monitoring of serum trough levels.